Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ELIZABETH ANN MITTENDORF and AYSEGUL A SAHIN.
Connection Strength

1.593
  1. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016 Jul 01; 2(7):929-36.
    View in: PubMed
    Score: 0.140
  2. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 07; 23(7):2242-8.
    View in: PubMed
    Score: 0.137
  3. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015 Apr 01; 33(10):1119-27.
    View in: PubMed
    Score: 0.126
  4. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.107
  5. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.100
  6. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
    View in: PubMed
    Score: 0.100
  7. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
    View in: PubMed
    Score: 0.097
  8. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer. 2010 Feb; 10(1):52-8.
    View in: PubMed
    Score: 0.090
  9. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
    View in: PubMed
    Score: 0.082
  10. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  11. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.057
  12. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.052
  13. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.048
  14. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.048
  15. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Oct; 25(10):2932-2938.
    View in: PubMed
    Score: 0.040
  16. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):568-577.
    View in: PubMed
    Score: 0.040
  17. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281.
    View in: PubMed
    Score: 0.038
  18. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
    View in: PubMed
    Score: 0.033
  19. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
    View in: PubMed
    Score: 0.030
  20. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One. 2014; 9(2):e89778.
    View in: PubMed
    Score: 0.030
  21. Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. 2014 Jan; 21(1):60-5.
    View in: PubMed
    Score: 0.029
  22. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.025
  23. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011 Oct; 11(5):325-31.
    View in: PubMed
    Score: 0.025
  24. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
    View in: PubMed
    Score: 0.025
  25. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81.
    View in: PubMed
    Score: 0.020
  26. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.